The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

The low-cost carrier is having a nightmarish 2024, with its shares down 86% even before Thursday's news. The chip maker invested about $100 million in OpenAI's latest funding round, The Wall Street ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

Levi Strauss cut its revenue outlook for the year and is once again exploring the potential sale of Dockers, the latest move by CEO Michelle Gass to focus the company on its namesake brand. The ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

Stocks declined on Thursday as rising tensions in the Middle East left investors uneasy ahead of September's payrolls report.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...